UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures
This article was originally published in The Pink Sheet Daily
Executive Summary
A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.